Barclays analyst Etzer Darout assumed coverage of CytomX Therapeutics (CTMX) with an Overweight rating and $3.50 price target The firm sees a positive risk/reward for the company’s lead clinical program CX-2051. CytomX’s cash runway will get it through the 2026 data catalysts, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- CytomX Therapeutics initiated with an Overweight at Barclays
- Barclays sees ‘significant potential’ in CytomX’s CX-2051 despite safety event
- CytomX trial ongoing despite grade five event, says Oppenheimer
- CytomX Therapeutics Updates on CX-2051 Phase 1 Study
- CytomX Therapeutics provides update on CX-2051 Phase 1 study